CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease

Danqing Kong; Changju Qu; Haiping Dai; Zheng Li; Jia Yin; Suning Chen; Liqing Kang; Guanghua Chen; Mingqing Zhu; Lei Yu; Depei Wu; Xiaowen Tang

doi:10.1111/bjh.16982

CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph⁺ mixed phenotype acute leukaemia with minimal residual disease

Br J Haematol. 2020 Oct;191(2):e47-e49. doi: 10.1111/bjh.16982. Epub 2020 Jul 22.

Authors

Danqing Kong^{1

2}, Changju Qu^{1

2}, Haiping Dai^{1

2}, Zheng Li^{1

2}, Jia Yin^{1

2}, Suning Chen^{1

2}, Liqing Kang^{3

4}, Guanghua Chen^{1

2}, Mingqing Zhu^{1

2}, Lei Yu^{3

4}, Depei Wu^{1

2}, Xiaowen Tang^{1

2}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou University, Suzhou, China.
³ School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
⁴ Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd., Shanghai, China.

PMID: 32700338
DOI: 10.1111/bjh.16982

No abstract available

Keywords: Philadelphia chromosome; allogeneic haematopoietic stem cell transplantation; chimeric antigen receptor; minimal residual disease; mixed phenotype acute leukaemia.

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Allografts
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunotherapy, Adoptive*
Leukemia, Biphenotypic, Acute* / blood
Leukemia, Biphenotypic, Acute* / therapy
Male
Middle Aged
Neoplasm, Residual
Philadelphia Chromosome*

Publication types

MeSH terms

Grants and funding